Clinical trials: Vehicle
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on the balding scalp when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547363
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- LEO Pharma
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Chronic Ocular Graft-versus-host Disease
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
- Trial name
- NCT03990051
- Testing
- Pro-ocular™ topical gel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Glia, LLC
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Dermatitis, Atopic
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2%…
- Trial name
- NCT03233529
- Testing
- Crisaborole ointment 2% BID
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pfizer
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye, Sjogren's Syndrome
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort.
- Conditions
- Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
- Trial name
- NCT01393132
- Testing
- Thymosin Beta 4 eye drops, Vehicle Control
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michigan Cornea Consultants, PC
Ketosis
Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More
This study aims to address two key aspects. First, the suitability of selecting a specific sampling site for BHB measurement in patients and research, as well as potential differences between capillary and venous blood…
- Trial name
- NCT06053138
- Testing
- Ketone monoester
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Central Jutland Regional Hospital
Dry Eye
A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution…
- Trial name
- NCT03598699
- Testing
- AXR-159, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- AxeroVision, Inc.
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis
Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of…
- Trial name
- NCT01700985
- Testing
- 122-0551, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Therapeutics, Inc.
Actinic Keratosis
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
- Trial name
- NCT02137785
- Testing
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
- Where
- 13 sites in United States
- Volunteers
- 269 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608476
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 52 sites in United States, Bulgaria and 4 more
- Volunteers
- 732 people
- Sponsor
- Cassiopea SpA
Hypertension
Chiropractic for Hypertension in Patients
The investigators propose a prospective randomized 2 arm parallel observer-blinded phase II clinical study comparing a distinct method of upper cervical chiropractic manipulation to a sham technique in 50 individuals with stage I…
- Trial name
- CHiP (NCT01020435)
- Testing
- Spinal Manipulation
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Palmer College of Chiropractic
Dry Eye Syndromes
Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease
This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.
- Trial name
- NCT02435914
- Testing
- AGN-223575 ophthalmic solution, AGN-223575 vehicle ophthalmic solution
- Where
- 28 sites in United States
- Volunteers
- 236 people
- Sponsor
- Allergan
Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis.
- Trial name
- NCT01745133
- Testing
- vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Leon Kircik, M.D.
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03839693
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eirion Therapeutics Inc.
IgA Nephropathy
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2…
- Trial name
- NCT03608033
- Testing
- OMS721, Vehicle (D5W or saline)
- Where
- 139 sites in United States, Argentina and 21 more
- Volunteers
- 360 people
- Sponsor
- Omeros Corporation
Submental Fat
Efficacy and Safety of RZL-012 on Submental Fat Reduction
A total of 135 eligible male or female subjects will be randomized according to a predetermined randomization scheme (1:1:1 ratio) to receive a single multi-injection treatment of high dose RZL-012, low dose RZL-012, or placebo…
- Trial name
- NCT04867434
- Testing
- RZL-012
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Raziel Therapeutics Ltd.
Psoriasis Vulgaris
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03308799
- Testing
- MC2-01 cream, Cal/BDP combination, Cream vehicle
- Where
- 3 sites in United States
- Volunteers
- 794 people
- Sponsor
- MC2 Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.